CM
BMY icon

Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.63M Sell
92,829
-7,684
-8% -$448K 0.96% 38
2025
Q4 		$5.42M Sell
100,513
-11,157
-10% -$537K 0.89% 40
2025
Q3 		$5.04M Buy
111,670
+9,815
+10% +$458K 0.79% 39
2025
Q2 		$4.71M Sell
101,855
-123,989
-55% -$6.09M 0.8% 40
2025
Q1 		$13.8M Sell
225,844
-10,625
-4% -$619K 2.39% 15
2024
Q4 		$13.4M Sell
236,469
-1,910
-0.8% -$107K 2.4% 16
2024
Q3 		$12.3M Buy
238,379
+31,103
+15% +$1.46M 2.19% 17
2024
Q2 		$8.61M Buy
207,276
+16,565
+9% +$741K 1.72% 23
2024
Q1 		$10.3M Buy
190,711
+7,633
+4% +$389K 1.97% 22
2023
Q4 		$9.39M Sell
183,078
-32,528
-15% -$1.71M 1.85% 25
2023
Q3 		$12.5M Sell
215,606
-1,952
-0.9% -$120K 2.83% 11
2023
Q2 		$13.9M Buy
217,558
+23,159
+12% +$1.55M 2.98% 9
2023
Q1 		$13.5M Buy
194,399
+36,202
+23% +$2.55M 3.09% 10
2022
Q4 		$11.4M Sell
158,197
-5,315
-3% -$401K 2.8% 12
2022
Q3 		$11.6M Sell
163,512
-3,443
-2% -$250K 3.28% 9
2022
Q2 		$12.9M Sell
166,955
-24,752
-13% -$1.89M 3.18% 10
2022
Q1 		$14M Sell
191,707
-23,364
-11% -$1.57M 2.99% 11
2021
Q4 		$13.4M Sell
215,071
-28,554
-12% -$1.67M 2.78% 14
2021
Q3 		$14.4M Sell
243,625
-22,732
-9% -$1.5M 3.15% 11
2021
Q2 		$17.8M Sell
266,357
-12,196
-4% -$795K 3.78% 4
2021
Q1 		$17.6M Buy
278,553
+73,665
+36% +$4.58M 3.93% 5
2020
Q4 		$12.7M Buy
204,888
+478
+0.2% +$29.4K 3.47% 9
2020
Q3 		$12.3M Buy
204,410
+3,478
+2% +$209K 3.87% 7
2020
Q2 		$11.8M Buy
200,932
+27,612
+16% +$1.65M 3.94% 7
2020
Q1 		$9.66M Buy
+173,320
New +$10.6M 3.54% 7
2019
Q1 		– Sell
-201,655
Closed -$10.5M – 84
2018
Q4 		$10.5M Buy
201,655
+8,481
+4% +$456K 3.25% 8
2018
Q3 		$12M Buy
193,174
+6,805
+4% +$404K 3.06% 8
2018
Q2 		$10.3M Buy
186,369
+149,187
+401% +$8.06M 2.77% 10
2018
Q1 		$2.35M Buy
+37,182
New +$2.39M 0.63% 45

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Management's BMY Position: Q1 2026 in Review

Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 7.6% in Q1 2026, selling an estimated $448K and leaving 92,829 shares worth $5.63M. The position accounts for 0.96% of the portfolio, ranked #38.

Capital Management first reported a position in BMY in Q1 2018 and has held it in 29 quarters since. The position peaked at $17.8M in Q2 2021. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Capital Management held 92,829 shares of Bristol-Myers Squibb worth $5.63M as of Q1 2026.
  • Capital Management sold 7,684 Bristol-Myers Squibb shares in Q1 2026, an estimated $448K.
  • Bristol-Myers Squibb made up 0.96% of Capital Management's portfolio in Q1 2026, its #38 holding.
  • Capital Management first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 29 quarters since.
  • Capital Management's Bristol-Myers Squibb position peaked at $17.8M in Q2 2021.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.